Table 2:

Prevalence of STK11 SNP in case and control groups

				STK11 Allele		Genotype %	Odds Ratio vs:
Cohort	Race	Gender	MS Type	C/T	C/C		VA White MS	ACP MS	AA Ctl	UCSF White MS	USCF White Ctl
VALOMS	AA	Male	RR	1	12	8%	0.6	0.6	0.7	0.8
			SP	2	5	29%	8.0	3.0	3.3	4.0
			Both	3	17	15%	1.8	1.3	1.5	1.8
		Female	RR	2	6	25%	1.7	2.5	2.2	2.7
			SP	2	3	40%	n/a	4.9	4.4	5.4
			Both	4	9	31%	5.3	3.3	2.9	3.6 c
		Both	RR	3	18	14%	1.1	1.2	1.2	1.4
			SP	4	8	33%	13.5 a	3.7 e	3.5 b	4.3
			Both	7	26	21%	2.9	2.0	1.9	2.3
	White	Male	RR	3	21	13%				1.4	1.4
			SP	1	20	5%				0.5	0.5
			Both	4	41	9%				1.0	1.0
		Female	RR	1	5	17%				1.6	2.1
			SP	0	7	0%				1.0	0.0
			Both	1	12	8%				1.5	1.0
		Both	RR	4	26	13%				1.3	1.7
			SP	1	27	4%	a			0.3	0.4
			Both	5	53	9%				1.2	1.1
ACP	AA	Male	RR	2	15	12%			1.1
		Female	RR	11	81	12%			0.9
		Both	RR	13	96	12%		e	0.9
VALOMS & ACP	AA	Male	RR	5	32	14%			1.3
		Female	RR	15	90	14%			1.1
		Both	RR	20	122	14%			1.1
ACP & USCF	AA	Male	Ctl	12	99	11%
		Female	Ctl	43	286	13%
		Both	Ctl	55	385	13%			b
UCSF	White	Male	RR	19	190	9%					1.1
		Female	RR	49	396	11%				c	1.6 d
		Both	RR	68	586	10%					1.5
	White	Male	Ctl	19	217	8%
		Female	Ctl	30	395	7%					d
		Both	Ctl	49	612	7%

^a,p=0.022

^b,p=0.058

^c,p= 0.052

^d,p=0.045

^e,p=0.065.

Fisher’s exact test. Letters are duplicated to facilitate comparisons. ACP, Accelerated Cure Project; RR, relapsing remitting; SP, secondary progressive